RxDoctor Payments Data

Jared Smedley, MD

Ophthalmology · Arvada, CONPI 1487074191

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 91.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $13,165 and has fallen 96.1% since, to $508 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,011in general payments, 2019–2025

Across 99 payments — averaging $222.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$20K
  • Alcon$545
  • AbbVie$408
  • Dompe US, Inc.$253
  • Bausch & Lomb Americas Inc.$134
  • Biotissue Holdings Inc.$125
  • plus $345 from 10 others

What the payments were for

  • Consulting fees$3,90018%
  • Speaking & faculty fees$11,60053%
  • Travel & lodging$3,40815%
  • Food & beverage$3,09314%
  • Education$100%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,011 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$175,032
Medicare patients
468
Services billed
1,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost51$31,994
RestasisCyclosporine20$27,701
CombiganBrimonidine Tartrate/Timolol11$4,659
Latanoprost306$4,172
Tobramycin-DexamethasoneTobramycin/Dexamethasone67$3,141
Prednisolone Acetate55$2,734
Timolol Maleate122$2,243
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat131$1,910
Brimonidine Tartrate26$1,906
MoxifloxacinMoxifloxacin Hcl64$1,466
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha54$674
Ketorolac Tromethamine20$289
Dorzolamide Hcl11$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$408$64,35482 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Arvada

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →